To assess the incidence of BCR‐ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP‐CML) patients treated with tyrosine kinase inhibitors (TKIs). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.